ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Gyre Therapeutics Inc

Gyre Therapeutics Inc (GYRE)

9.81
-2.47
( -20.11% )
Updated: 08:39:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
9.81
Bid
9.71
Ask
9.82
Volume
49,437
9.43 Day's Range 11.50
8.26 52 Week Range 19.00
Market Cap
Previous Close
12.28
Open
11.50
Last Trade
100
@
9.81
Last Trade Time
08:39:00
Financial Volume
US$ 502,983
VWAP
10.1742
Average Volume (3m)
87,322
Shares Outstanding
93,521,434
Dividend Yield
-
PE Ratio
-9.75
Earnings Per Share (EPS)
-0.99
Revenue
113.45M
Net Profit
-92.93M

About Gyre Therapeutics Inc

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalc... Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Gyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GYRE. The last closing price for Gyre Therapeutics was US$12.28. Over the last year, Gyre Therapeutics shares have traded in a share price range of US$ 8.26 to US$ 19.00.

Gyre Therapeutics currently has 93,521,434 shares outstanding. The market capitalization of Gyre Therapeutics is US$1.15 billion. Gyre Therapeutics has a price to earnings ratio (PE ratio) of -9.75.

GYRE Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.17-10.655737704910.9812.628.811710447411.78344618CS
4-2.41-19.721767594112.2213.758.81178851411.28469827CS
12-2.39-19.590163934412.214.42288.81178732211.20846256CS
26-4.25-30.227596017114.06198.81178471211.78753945CS
52-7.19-42.294117647117198.267086312.56240608CS
1562.8140.1428571429730.45.888028414.93629375CS
2602.8140.1428571429730.45.888028414.93629375CS

GYRE - Frequently Asked Questions (FAQ)

What is the current Gyre Therapeutics share price?
The current share price of Gyre Therapeutics is US$ 9.81
How many Gyre Therapeutics shares are in issue?
Gyre Therapeutics has 93,521,434 shares in issue
What is the market cap of Gyre Therapeutics?
The market capitalisation of Gyre Therapeutics is USD 1.15B
What is the 1 year trading range for Gyre Therapeutics share price?
Gyre Therapeutics has traded in the range of US$ 8.26 to US$ 19.00 during the past year
What is the PE ratio of Gyre Therapeutics?
The price to earnings ratio of Gyre Therapeutics is -9.75
What is the cash to sales ratio of Gyre Therapeutics?
The cash to sales ratio of Gyre Therapeutics is 7.99
What is the reporting currency for Gyre Therapeutics?
Gyre Therapeutics reports financial results in USD
What is the latest annual turnover for Gyre Therapeutics?
The latest annual turnover of Gyre Therapeutics is USD 113.45M
What is the latest annual profit for Gyre Therapeutics?
The latest annual profit of Gyre Therapeutics is USD -92.93M
What is the registered address of Gyre Therapeutics?
The registered address for Gyre Therapeutics is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Gyre Therapeutics website address?
The website address for Gyre Therapeutics is www.gyretx.com
Which industry sector does Gyre Therapeutics operate in?
Gyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SYRSSyros Pharmaceuticals Inc
US$ 0.167
(94.64%)
158.74M
INDPIndaptus Therapeutics Inc
US$ 1.27
(56.35%)
948.64k
RGCRegencell Bioscience Holdings Ltd
US$ 25.72
(39.03%)
805.44k
VINCVincerx Inc
US$ 1.10
(32.69%)
6.35M
HROWHarrow Inc
US$ 30.23
(29.63%)
281.68k
ATXIAvenue Therapeutics Inc
US$ 0.4904
(-42.45%)
268.54k
AGMHAGM Group Holdings Inc
US$ 0.0667
(-36.84%)
13.02M
OMOutset Medical Inc
US$ 0.39385
(-31.87%)
794.57k
JAGXJaguar Health Inc
US$ 0.3211
(-31.54%)
297.13k
ANTEAirNet Technology Inc
US$ 1.11
(-31.06%)
4.11M
SYRSSyros Pharmaceuticals Inc
US$ 0.1669
(94.52%)
158.91M
LITMSnow Lake Resources Ltd
US$ 0.494
(18.69%)
44.72M
GNPXGenprex Inc
US$ 0.4684
(17.10%)
29.8M
SCNXScienture Holdings Inc
US$ 2.87
(15.73%)
29.75M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.60
(-8.87%)
22.38M